Back to Sectors

PFSA

Profusa, Inc.
3 filings tracked
healthcarebiotechnologyMICRO (<$300M)

Signal Magnitude Chart

BULLISH | 70% | 5/15/2026 | capital raiseBEARISH | 90% | 5/15/2026 | margin compressionNEUTRAL | 50% | 5/15/2026 | debt restructureBEARISH | 80% | 5/15/2026 | regulatory actionBULLISH | 60% | 5/15/2026 | acquisitionBULLISH | 70% | 5/15/2026 | capital raiseBEARISH | 90% | 5/15/2026 | margin compressionNEUTRAL | 50% | 5/15/2026 | debt restructureBEARISH | 80% | 5/15/2026 | regulatory actionBULLISH | 60% | 5/15/2026 | acquisitionBULLISH | 70% | 5/26/2026 | acquisitionBULLISH | 60% | 5/26/2026 | dilution riskNEUTRAL | 50% | 5/26/2026 | capital raiseMay 26May 26HIGHLOW
bullish
bearish
neutral

Signal Timeline

bullishMay 26

Acquisition of PanOmics Assay expands precision medicine capabilities.

acquisition
70%
bullishMay 26

Elimination of a planned 12% management equity grant reduces immediate dilution.

dilution risk
60%
neutralMay 26

Issuance of $30M in convertible preferred stock to fund acquisition.

capital raise
50%
bullishMay 15

Secured $88.9 million available under an Equity Line of Credit (ELOC) to fund operations.

capital raise
70%
bearishMay 15

Operating loss widened to $4.0 million as G&A expenses surged 189% year-over-year.

margin compression
90%
neutralMay 15

Converted $1.9 million in related-party debt to equity to reduce cash liabilities.

debt restructure
50%
bearishMay 15

Forced transfer to Nasdaq Capital Market following failure to meet minimum bid price and market value requirements.

regulatory action
80%
bullishMay 15

Acquired Bio Insights' PanOmics Assay for $30 million in stock to expand into multi-omics.

acquisition
60%
bullishMay 15

Secured $88.9 million available under an Equity Line of Credit (ELOC) to fund operations.

capital raise
70%
bearishMay 15

Operating loss widened to $4.0 million as G&A expenses surged 189% year-over-year.

margin compression
90%
neutralMay 15

Converted $1.9 million in related-party debt to equity to reduce cash liabilities.

debt restructure
50%
bearishMay 15

Forced transfer to Nasdaq Capital Market following failure to meet minimum bid price and market value requirements.

regulatory action
80%
bullishMay 15

Acquired Bio Insights' PanOmics Assay for $30 million in stock to expand into multi-omics.

acquisition
60%

Filing History

8-KMay 26, 2026

The filing reveals a complex transition for Profusa as it pivots toward a multi-omics strategy. The acquisition of the PanOmics platform provides a tangible technological asset, but the financial engineering surrounding the deal—specifically the use of convertible preferred stock—leaves the door open for future equity dilution. Investors must weigh the strategic value of the new technology against the potential for volatility as the company manages its capital structure and executive alignment.

10-QMay 15, 2026

The Q1 2026 filing presents a company at a critical crossroads, where aggressive strategic expansion is clashing with a precarious balance sheet. On one hand, the acquisition of Bio Insights and the Mayo Clinic partnership suggest a vision for a diversified, multi-omics platform. On the other, the reality of a $28.4 million working capital deficit and a 'going concern' warning from management underscores the fragility of the enterprise. The company is effectively trading equity and taking on high-interest debt to fund the race toward its 2026 product launches. For investors, the central tension lies in whether the upcoming commercialization of Lumee Glucose and Lumee Oxygen can generate cash flow before the remaining liquidity is exhausted. The successful execution of the dual-launch strategy is no longer just a growth goal—it is a survival requirement. While the secured funding lines provide a temporary reprieve, the combination of material internal control weaknesses and persistent Nasdaq compliance issues suggests that the operational risk remains exceptionally high.